Table 1 compiles the information regarding the expression of the above-mentioned biomarkers in the human HCC cells lines for which more published information can be found, according to their TGF-β signature. Recent pharmacological studies with Galunisertib, a TβRI kinase inhibitor, are also allowing the identification of biomarkers that may help to calculate the benefit and/or to follow up the potential efficiency of TGF-β blockers in the progression of HCC [39]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.